Effects of antiepileptic drugs on mood and behavior

Epilepsia

Volumn 47, Issue SUPPL. 2, 2006, Pages 28-33

  Schmitz, Bettina ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Forced normalization; Idiosyncratic side effects; New antiepileptic drugs; Positive psychotropic effects; Psychiatric adverse events

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; AGGRESSION; AGITATION; AMNESIA; ANXIETY; ARTICLE; ATAXIC APHASIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BLOOD TOXICITY; BRAIN DISEASE; CLINICAL TRIAL; CONDUCT DISORDER; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; EXCITABILITY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENERALIZED ANXIETY DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERKINESIA; HYPOMANIA; INCIDENCE; INSOMNIA; IRRITABILITY; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MENTAL DEFICIENCY; MENTAL DISEASE; META ANALYSIS; MOOD DISORDER; NERVOUSNESS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; PSYCHOSOCIAL DISORDER; RAPID CYCLING BIPOLAR DISORDER; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SLEEP DISORDER; SOMNOLENCE; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTICONVULSANTS; ELECTROENCEPHALOGRAPHY; HUMANS; MENTAL DISORDERS; MOOD DISORDERS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33750583237     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00684.x     Document Type: Article

References (49)

1. Schmitz B, Robertson M, Trimble MR. Depression and schizophrenia in epilepsy: social and biological risk factors. Epilepsy Res 1999;35:59-68.
2. Matsuura M. Epileptic psychoses and anticonvulsant drug treatment. J Neurol Neurosurg Psychiatry 1999;67:231-3.
3. Robertson MM, Trimble MR, Townsend HRA. Phenomenology of depression in epilepsy. Epilepsia 1987;28:364-72.
4. Brent DA. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children's hospital, 1978-1983. J Am Acad Child Psychiatry 1986;25:242-6.
5. Brent DA, Crumrine PK, Varma RR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909-17.
6. McDanal CE, Bolman WM. Delayed idiosyncratic psychosis with diphenylhydantoin. JAMA 1975;231:1063.
7. Kanemoto K, Tsuji T, Kawasaki J. Reexamination of interictal psychoses based on DSMIV psychosis classification and international epilepsy classification. Epilepsia 2001;42:98-103.
8. Trimble MR, Reynolds EH. Anticonvulsant drugs and mental symptoms: a review. Psychol Med 1976;6:169-78.
9. Wolf P, Inoue Z, Röder-Wanner UU, et al. Psychiatric complications of absence therapy and their relation to alteration of sleep. Epilepsia 1984;25:56-9.
10. Dalby MA. Behavioral effects of carbamazepine. In: Penry JK, Daly DD, eds. Complex partial seizures and their treamtent. Advances in Neurology. Vol. 11. New York: Raven, 1975, pp. 331-43.
11. Drake ME, Peruzzi WT. Manic state with carbamazepine therapy of seizures. J Natl Med Assoc 1986;78:1105-7.
12. Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other convulsant drugs. Epilepsia 1979;20:697-703.
13. Zaret BS, Cohen RA. Reversible valproic acid-induced dementia: a case report. Epilepsia 1986;27:234-40.
14. Schöndienst M, Wolf P. Zur Möglichkeit neurotoxischer Spätwirkungen von Valproinsäure. In: Krämer G, Laub M, eds. Valproinsäure. Berlin, Heidelberg, New York: Springer, 1992:259-65.
15. Sander JWAS, Hart ZM, Trimble MR, et al. Vigabatrin and psychosis. JNNP 1991;54:435-9.
16. Thomas L, Trimble MR, Schmitz B, et al. Vigabatrin and behaviour disorders: A retrospective study. Epilepsy Res 1996;25:21-7.
17. Dulac O, Chiron D, Cusmai R, et al. Vigabatrin in childhood epilepsy. J Child Neurol 1991;6(suppl. 2):30-37.
18. Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996;93:1-8.
19. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999;53:1503-11.
20. Fitton A, Goa KL. Lamotrigine. Drugs 1995;50:691-713.
21. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995;345:476-9.
22. Binnie DB. Lamotrigine. In: Engel J, Pedley TA, eds. Epilepsy. A comprehensive textbook. Philadelphia, New York: Lippincott-Raven, 1997;1531-40.
23. Besag FMC. Behavioural effects of the new anticonvulsants. Drug Saf 2001;24:513-536.
24. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:280-82.
25. Ettinger AB, Weisbrot DM, Saracco J, et al. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
26. Lombroso CT. Lamotrigine-induced tourettism. Neurology 1999;52:1191-4.
27. Essex Pharma, Felbamate: Product Monograph. 1996.
28. McConnell H, Snyder PJ, Duffy JD, et al. Neuropsychiatric side effects related to treatment with felbamate. J Neuropsychiatry Clin Neurosci 1996;8:341-6.
29. Lee DO, Steingard RJ, Cesena M, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90.
30. Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1996;36:1203-5.
31. Tallian KB, Nahata MC, Lo W, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37:501-2.
32. Schapel G, Chadwick D. Tiagabine and non-convulsive status epilepticus. Seizure 1996;5:153-6.
33. Leppik E. Tiagabine: the safety landscape. Epilepsia 1995;36(suppl. 6):10-13.
34. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998.
35. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-63.
36. Janssen-Cilag. Topamax. Product monograph, 1996.
37. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61:704-6.
38. Trimble MR. Neuropsychiatric consequences of pharmacotherapy. In: Engel J, Pedley TA, eds, Epilepsy. A comprehensive textbook. Philadelphia, New York: Lippincott-Raven, 1997, pp. 2161-70.
39. Cramer JA, Blum D, Reed M, Fanning K; Epilepsy Impact Project Group. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav 2003;4:515-21.
40. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(suppl. 2):53-67.
41. Landolt H. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorentz de Haas AM, ed. Lectures on epilepsy. Amsterdam: Elsevier, 1958, pp. 91-131.
42. Gatzonis SD, Stamboulis E, Siafakas A, et al. Acute psychosis and EEG normalisation after vagus nerve stimulation. J Neurol Neurosurg Psychiatr 2000;69:278-9.
43. Walden J, Normann C, Langosch J, et al. Differential treatment of bipolar disorders with old and new antiepileptic drugs. Neuropsychobiology 1998;38:181-4.
44. Calabrese J, Bowden C, Sachs G, et al. A double blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88.
45. Kasumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997;19:145-8.
46. Letterman L, Markowitz JS. Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy 1999;19:565-72.
47. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
48. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999;13:194-9.
49. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.